Swiss pharma giant Roche has announced “positive” results from clinical trials of an anti-Covid cocktail developed with US biotech firm Regeneron, AFP reported.

The results of the Phase 3 trial, “shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70 per cent in non-hospitalised patients with Covid-19,” it said in a statement.

The cocktail also “significantly shortened the duration of symptoms by four days”.